Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

108.73 -0.25 (-0.23%)
Streaming Delayed Price Updated: 11:15 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
Is Big Pharma Coming For Your Cannabis Business?
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies... 
Via Benzinga
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
The cannabis sector has been disappointing in recent years, but this company stands out. 
Via The Motley Fool
Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain
Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK.  
Via Benzinga
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue. 
Via Benzinga
The Latest Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Earnings Preview For Jazz Pharmaceuticals
Via Benzinga
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
Via Benzinga
Zymeworks Offers Hope for More than Just Long-Term Investors
Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher 
Via MarketBeat
With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path
The global CBD market is on an upward trajectory, and there are no indications that the growth could be slowing down anytime soon. The market was valued at $5.18 billion in 2021 and is expected to... 
Via Benzinga
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various... 
Via Benzinga
Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains
It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers... 
Via Benzinga
2 Cannabis Stocks to Buy for the Long Haul
Don't give up on this sector too quickly. 
Via The Motley Fool
Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights 
Via Benzinga
Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says
The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis. 
Via Benzinga
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of... 
Via Talk Markets
2 Cannabis Stocks That Could Make You Richer
These two stocks could grow like weeds in the next five years and beyond. 
Via The Motley Fool
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from... 
Via Benzinga
3 Cannabis Stocks With Double-Digit Percentage Revenue Growth
Their shares may be down, but their sales are up. 
Via The Motley Fool
The Ultimate Growth Stocks to Buy With $300 Right Now
These three companies should deliver inflation-busting long-term growth. 
Via The Motley Fool
2 Promising New Growth Stocks to Watch in 2023
These stocks have plenty of room to run. 
Via The Motley Fool
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
Via Benzinga
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
There are still plenty of growth opportunities left for these businesses. 
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
These stocks look cheap if you take a long-term view. 
Via The Motley Fool
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS 
Via Benzinga
2 Growth Stocks to Buy Heading Into 2023
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Better Buy: Moderna vs Axsome
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.